FDA Brief

Warning letters Drugs

FDA warning letter to

BBC Group Limited

High riskIssued Aug 4, 2021Posted Aug 10, 2021Center for Drug Evaluation and Research

FDA cites BBC Group Limited for data integrity, lab, equipment failures and unapproved, misbranded hand sanitizers.

What happened

FDA inspected the drug manufacturing facility from March 22 to March 26, 2021 and found data integrity failures, inadequate test-method validation, and rust on product-contact equipment. FDA also found L.O.L. SURPRISE! scented hand sanitizers were unapproved new drugs and misbranded, and the company remains on Import Alert 66-40, which can block U.S. imports.

What FDA found

  1. FDA found gas chromatograph data from 2018 to 2020 was lost and unrecoverable, users shared a no-password 'System Administrator' login, audit trails were disabled, and stability spreadsheets were unprotected.

    21 CFR 211.68(b)
  2. FDA found analytical test methods, including for ethanol and an impurity, were not adequately validated and lacked system suitability requirements and identified reference standards.

    21 CFR 211.160(b)
  3. FDA observed rust on product-contact surfaces of four pieces of manufacturing equipment and found that maintenance records provided were for different equipment.

    21 CFR 211.67(a)
  4. L.O.L. SURPRISE! scented hand sanitizers were marketed as unapproved new drugs without FDA approval or meeting the conditions for marketing without an application.

    FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)
  5. The hand sanitizers were misbranded because they did not comply with section 505G requirements for nonprescription drugs.

    FD&C Act section 502(ee), 21 U.S.C. 352(ee)
  6. FDA found the firm lacked analytical data supporting drug product release and that records submitted before inspection were inconsistent with raw data seen during inspection.

    21 CFR 211.165; FD&C Act section 704(a)(4), 21 U.S.C. 374(a)(4)

What FDA wants

FDA tells BBC Group Limited to correct the violations promptly and to provide comprehensive investigations, risk assessments, and corrective action plans for data integrity, laboratory controls, and equipment maintenance. FDA recommends an independent qualified CGMP consultant; the letter does not state a specific response deadline.

Who should pay attention

  • brands and retailers selling L.O.L. SURPRISE! hand sanitizers
  • companies buying OTC drugs from Chinese contract manufacturers
  • quality teams responsible for laboratory data integrity and supplier oversight

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Pritam International Private Limited

    Pritam International, an Indian OTC drug maker, was cited for CGMP violations, falsified lab data, unsafe color additive, and DEG/EG testing gaps.

    High risk
  3. Conroe Welding Supply, Inc.

    FDA warns Conroe Welding Supply over medical oxygen manufacturing failures, including untested batches and a container with 99% (b)(4).

    High risk
  4. SnugZ USA, Inc.

    SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.

    High risk